Accueil   Diary - News   All news Eurostars Funds IMPACT2 To Establish A Break-Through Translational AMR Platform

Eurostars Funds IMPACT2 To Establish A Break-Through Translational AMR Platform

 

BioSystems Technology, BioVersys and Voxcan join forces to establish IMPACT2 - an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars - a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme.

 

 

BioSystems Technology, BioVersys and Voxcan announce funding for a total of about € 840’000, by Eurostars over a 3-year period for IMPACT2, a break-through innovative translational AMR platform that will expedite the development of novel new medicines in the fight against antimicrobial resistance.

 


New treatments are urgently needed to combat high mortality rates due to the untreatable infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens such as K. pneumoniae, A. baumannii, P. aeruginosa, E. coli and others. Novel intervention strategies are vital to respond to the AMR crisis however, current drug discovery tools are inadequate to properly address resistant pathogen strains.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree